Aurinia Pharmaceuticals Inc. - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Aurinia Pharmaceuticals Inc., a foreign private issuer, on June 30, 2016. The filing serves to distribute a Material Change Report dated June 15, 2016, to the U.S. Securities and Exchange Commission.
Financial Metrics
The provided filing text contains only cover page and signature information. It does not include specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics.
Material Changes
The filing references a Material Change Report (Exhibit 99.1) dated June 15, 2016. However, the text of this report is not included in the provided input, so the specific nature of the material change cannot be summarized.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risk factors, or details on contingencies and unusual items.
Key Facts for Investor Verification
- Verify the specific content of the Material Change Report dated June 15, 2016, which is referenced as Exhibit 99.1 but not included in this text.
- Confirm the company's current financial status and operational updates through the full Material Change Report or subsequent filings.
- Note that this Form 6-K is a procedural filing to distribute the Material Change Report and does not contain standalone financial statements.